Brad Barnett
Chief Tech/Sci/R&D Officer presso COGENT BIOSCIENCES, INC.
Profilo
Brad Barnett is currently the Chief Technology Officer at Cogent Biosciences, Inc. Prior to his current position, he worked at Array BioPharma, Inc. from 2000 to 2019, where he held the position of Vice President-Supply Chain & Manufacturing from 2015 to 2019.
Mr. Barnett received an undergraduate degree from Colorado State University and an MBA from The University of Colorado.
Posizioni attive di Brad Barnett
| Società | Posizione | Inizio |
|---|---|---|
| COGENT BIOSCIENCES, INC. | Chief Tech/Sci/R&D Officer | - |
Precedenti posizioni note di Brad Barnett
| Società | Posizione | Fine |
|---|---|---|
| ARRAY TECHNOLOGIES, INC. | Corporate Officer/Principal | 01/08/2019 |
Formazione di Brad Barnett
| Colorado State University | Undergraduate Degree |
| The University of Colorado | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| COGENT BIOSCIENCES, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Array BioPharma, Inc.
 Array BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Array BioPharma, Inc. is a biopharmaceutical company. Its focus is on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. The company's products are BRAFTOVI and MEKTOVI. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. The company was founded by Kevin Koch, Anthony D. Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO. | Health Technology |
- Borsa valori
- Insiders
- Brad Barnett
